

May 17, 2017

| | |
|--|--|
| To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA | To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804 |
|--|--|

Dear Sir,

Sub: Board Meeting to consider the Audited Financial Results of the Company for the year ended 31st March 2017 and the Proposal of payment of Dividend.


We hereby inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a Meeting of the Board of Directors of the Company will be held on **Monday, 29th May 2017** to consider and approve, inter alia, the Audited Financial Results of the Company for the year ended 31st March 2017 and also to consider dividend, if any, for the financial year 2016-17.

Further to our letter dated 12th May 2017 informing the closure of Trading Window of the Company from 18th May 2017 until 48 hours from the date of declaration of the Audited Financial Results of the Company for the year ended 31st March 2017, we would like to inform you that the trading window will be closed up to 31st May 2017 and shall be re-opened on 1st June, 2017.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED


B. Adi Reddy
Company Secretary

